# Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

> **NCT05420493** · PHASE1 · UNKNOWN · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 54 (estimated)

## Conditions studied

- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** CAR-T cells

## Key facts

- **NCT ID:** NCT05420493
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-06
- **Primary completion:** 2024-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420493, "Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05420493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*